Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Handbook of Clinical Neurology
|
August 10, 2020
Neuroimmunologic disorders in pregnancy
Seth Levin, Kathryn Rimmer, Wendy S Vargas
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
September 11, 2023
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew A Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Psychopharmacology
|
September 20, 2024
Effects of zuranolone on next-day simulated driving in healthy adults
Joi Dunbar, Gaetano Morelli, Rakesh Jain, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 3, 2024
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry
Kerstin Hellwig, David Rog, Christopher McGuigan, et al.
Multiple Sclerosis and Related Disorders
|
October 11, 2024
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study
Samuel F Hunter, John W Lindsey, Benjamin Osborne, et al.
Journal of Psychopharmacology (Oxford, England)
|
October 12, 2024
Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial
Joi Dunbar, David P Walling, Howard A Hassman, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
August 28, 2020
Fatal COVID-19 in an MS patient on natalizumab: A case report
Kathryn Rimmer, Rebecca Farber, Kiran Thakur, et al.
Neurology and Therapy
|
June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study
Barry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
The Journal of Clinical Psychiatry
|
December 28, 2023
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study
Andrew J Cutler, Gregory W Mattingly, Susan G Kornstein, et al.
Multiple Sclerosis and Related Disorders
|
September 3, 2021
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses
Samantha E Epstein, Seth Levin, Kaho Onomichi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Handbook of Clinical Neurology
|
August 10, 2020
Neuroimmunologic disorders in pregnancy
Seth Levin, Kathryn Rimmer, Wendy S Vargas
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
September 11, 2023
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew A Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Psychopharmacology
|
September 20, 2024
Effects of zuranolone on next-day simulated driving in healthy adults
Joi Dunbar, Gaetano Morelli, Rakesh Jain, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 3, 2024
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry
Kerstin Hellwig, David Rog, Christopher McGuigan, et al.
Multiple Sclerosis and Related Disorders
|
October 11, 2024
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study
Samuel F Hunter, John W Lindsey, Benjamin Osborne, et al.
Journal of Psychopharmacology (Oxford, England)
|
October 12, 2024
Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial
Joi Dunbar, David P Walling, Howard A Hassman, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
August 28, 2020
Fatal COVID-19 in an MS patient on natalizumab: A case report
Kathryn Rimmer, Rebecca Farber, Kiran Thakur, et al.
Neurology and Therapy
|
June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study
Barry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
The Journal of Clinical Psychiatry
|
December 28, 2023
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study
Andrew J Cutler, Gregory W Mattingly, Susan G Kornstein, et al.
Multiple Sclerosis and Related Disorders
|
September 3, 2021
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses
Samantha E Epstein, Seth Levin, Kaho Onomichi, et al.
Page
of 2